Cite
van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, et al. Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures. Trials. 2021;22(1):578doi: 10.1186/s13063-021-05457-5.
van Koningsbruggen-Rietschel, S., Dunlevy, F., Bulteel, V., Hayes, K., Verbrugge, A., Janssens, H. M., Dufeu, N., Simmonds, N. J., Dupont, L. J., & Downey, D. G. (2021). Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures. Trials, 22(1), 578. https://doi.org/10.1186/s13063-021-05457-5
van Koningsbruggen-Rietschel, Silke, et al. "Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures." Trials vol. 22,1 (2021): 578. doi: https://doi.org/10.1186/s13063-021-05457-5
van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Hayes K, Verbrugge A, Janssens HM, Dufeu N, Simmonds NJ, Dupont LJ, Downey DG. Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures. Trials. 2021 Aug 28;22(1):578. doi: 10.1186/s13063-021-05457-5. PMID: 34454570; PMCID: PMC8402966.
Copy
Download .nbib